resTORbio (NASDAQ:TORC) posted its earnings results on Wednesday. The company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.12), Fidelity Earnings reports.
Shares of TORC stock traded up $0.43 on Thursday, reaching $9.77. The stock had a trading volume of 312 shares, compared to its average volume of 213,002. The firm has a market cap of $331.34 million, a PE ratio of -6.91 and a beta of 3.26. resTORbio has a 1 year low of $6.21 and a 1 year high of $16.66. The stock’s 50 day simple moving average is $10.13.
A number of research firms have commented on TORC. Zacks Investment Research lowered resTORbio from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Guggenheim began coverage on resTORbio in a report on Tuesday, June 4th. They issued a “buy” rating and a $28.00 target price for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.50.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Further Reading: What is Put Option Volume?
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.